Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Automate Your Wheel Strategy on SHPH
With Tiblio's Option Bot, you can configure your own wheel strategy including SHPH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SHPH
- Rev/Share 0.0026
- Book/Share 0.6242
- PB 2.1629
- Debt/Equity 0.4787
- CurrentRatio 1.6621
- ROIC -5.2684
- MktCap 1445544.0
- FreeCF/Share -5.0137
- PFCF -0.1291
- PE -0.2817
- Debt/Assets 0.1884
- DivYield 0
- ROE -4.761
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Shuttle Pharmaceuticals Acquires AI Health Platform
Published: November 21, 2025 by: Newsfile Corp
Sentiment: Neutral
Rockville, Maryland--(Newsfile Corp. - November 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle" or the "Company") today announced that it has closed the acquisition of the assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies.
Read More
Shuttle Executes LOI with Molecule.ai
Published: October 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company, today announced the execution of a non-binding letter of Intent with Molecule.ai.
Read More
Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it entered into a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for potential acquisitions, marketing and other general corporate purposes.
Read More
Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT) announces that the reverse stock split will become effective on June 16, 2025, at 12:01 a.m.
Read More
Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering
Published: March 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today the pricing of an underwritten public offering of 19,166,667 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.30 per share (the “Offering”). The aggregate gross proceeds to Shuttle Pharma from the Offering are expected to be approximately $5.75 million, before deducting underwriting discounts and commissions and other estimated offering …
Read More
Shuttle Pharma Provides Corporate Update and Reports 2024 Results
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
GAITHERSBURG, Md., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2024.
Read More
About Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
- IPO Date 2022-08-31
- Website https://www.shuttlepharma.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Christopher Robert Cooper BBA,
- Employees 9